spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Safe’n’Spray™, the smart electronic concept device with child-resistant and locking features, wins the ‘Best Innovation In Drug Delivery Device’ Award at Pharmapack 2020

Nemera

A team of industry experts awarded Nemera’s Safe’n’Spray with a prestigious Pharmapack Award for ‘Best Innovation in Drug Delivery Device’.

On February 5th, during the Pharmapack Awards Ceremony, Safe’n’Spray, Nemera’s smart electronic concept device with child-resistant and locking features, was celebrated as the “Best Innovation in Drug Delivery Device”.

Safe’n’Spray is an integrated device with reusable electronic locking unit and fingerprint identification, to monitor drug delivered and prevent patient from overdosing. Safe'n'Spray responds to specific needs of controlling the doses delivered to patients in a defined period of time, in order to prevent any overdosing.

Indeed, Safe'n'Spray offers maximum safety for patients while using multidose potent drug products, without any risk of overdosing compared to other systems (e.g. unit-dose).

Moreover, Safe'n'Spray offers a unique possibility to reuse the "SAFE" electronic part once the "SPRAY" part with the drug is over (eco-friendly on both economic and ecologic sides).


The fingerprint sensor for patient unique identification acts as an easy and intuitive child-resistant feature, without the need for adding any secondary packaging with a Child resistant function.

Opposite to fully integrated devices, Safe'n'Spray does not change the manufacturing process of primary packaging on existing filling lines, as another module will deal with assembling Safe'n'Spray around primary packaging.

Last but not least, Safe'n'Spray is a connected device, linked with e-Nemera Cloud Solution, Nemera’s cloud platform. It offers access to patients, healthcare professionals and pharma companies for various services: treatment management, statistical analysis, etc.

“We are very proud to receive this prestigious award.” – said Marc Hämel, Nemera’s CEO – “According to the World Health Organization, overdose deaths contribute to between roughly a third and a half of all drug-related deaths, which are attributable in most cases to opioids. With Safe’n’SprayTM, we offer a solution to prevent any overdosing thanks to the different electronic features. This product is also user-friendly, child-resistant and sustainable, with a reusable electronic locking unit. Receiving the Pharmapack ‘Best Innovation in Drug Delivery Device’ Award is a great recognition for all our teams working every day to improve patients’ lives with innovative ideas.”



Launched in 1997, the Pharmapack Awards celebrate the latest innovations from packaging companies within the drugs, medical devices, health products and veterinary drugs sectors.

Safe’n’Spray at a glance:

Benefits for patients:
- Prevent overdosing of potent drugs (e.g. breakthrough pain)
- Intuitive and easy to use (fingerprint identification & simple display)

KEY DIFFERENTIATORS
- Reusable electronic locking unit for cost-savings
- Fingerprint for patient ID and as a smart child resistant function
- Simple display (doses left, remaining time for the next dose, feedback in case of misuse) 
- Relevant data available through e-Nemera cloud system

You can learn more about Safe’n’Spray at https://www.nemera.net/products/ear-nasal-throat/safenspray/
phone +33 4 74 94 06 54
email information@nemera.net
web www.nemera.net
email 20 avenue de la Gare, 38290 – La Verpillière, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Peli BioThermal showcase CoolPall™ Flex and industry leading solutions at Temperature Control and Logistics Conference

Peli BioThermal, the global name in temperature-controlled packaging, is exhibiting its industry leading shipper systems, including its innovative CoolPall™ Flex, at the 19th Annual Cool Chain Temperature Control and Logistics conference.
More info >>


White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement